Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib

haiyan ge,songshi ni,xiaocong fang,nuo xu,ying liu,yuanlin song,chunxue bai

IF: 24.3

2012-01-01

European Respiratory Journal

Abstract:Backgrounds and aims: Crizotinib has also demonstrated the development of acquired drug resistance. Despite secondary mutation, resistance of crizotinib may also be influenced by tumor microenvironment. Senescent cells display a senescence-associated secretory phenotype (SASP) involving the production of inflammatory cytokines that alter tumor microenvironment. Here, we analyzed the level of IL-6 and its signaling pathway in NSCLC cells and assessed the efficacy of IL-6 inhibitor madindoline A in combination with crizotinib in vivo. Methods: We detected senescence, SASP, IL-6/STAT3 and PI3K/AKT/mTOR signaling after crizotinib treatment in the presence or absence of madindoline A in NSCLC cell lines. The in vivo effect of the combination of crizotinib and madindoline A was assessed by tumor growth experiments using xenograft tumors. Results: Crizotinib induced tumor cellular senescence with senescent characteristics including increased senescence-associated β-galactosidase activity and higher expression SASPs. Depletion of the key IL-6R signaling component STAT3 by RNA interences markedly increased crizotinib-induced NSCLCs apoptosis in the addition of IL-6. When madindoline A and crizotinib were used in combination, they inhibited all the tested kinases in the IL-6/STAT3 and PI3K/AKT/mTOR pathways. Combined treatment with madindolin A and crizotinib exhibited significant inhibition of tumor growth in NSCLC cell xenografts in nude mice. Conclusions: We show that IL-6 is essential for the survival of premature senescence NSCLC cells treated with crizotinib. Study of the syngeneic model demonstrated the superior potency of the crizotinib combined with madindoline A.